The World Health Organisation's (WHO) panel of experts has recommended a third dose of US biotechnology company Novavax's (Nasdaq:NVAX) COVID-19 vaccine, NVX-CoV2373, for immunocompromised persons, Reuters news agency reported on Wednesday.
The WHO's Strategic Advisory Group of Experts on Immunisation (SAGE) issued a series of recommendations, including the use of the COVID-19 vaccine in persons with comorbidities, breastfeeding women and those living with HIV.
Also, after reviewing Novavax data the independent experts said the vaccine could be used in pregnant women if the benefits of vaccination to the pregnant woman outweigh the potential risks.
On Monday, Novavax said it had received the WHO's emergency use listing for the company's own version of the vaccine, which it will distribute in Europe and other markets.
Novovax also it had begun administering its first booster doses of NVX-CoV2373 in a late-stage trial.
genedrive secures initial overseas orders for Genedrive MT-RNR1 ID kit
Kromek collaborates on next-gen CT detector technology
Gilead Sciences initiates Phase 2 trial in Europe to evaluate lenacapavir for HIV prevention
European Commission grants authorisation to ViiV Healthcare's Apretude for prevention of HIV
Celanese to supply VitalDose drug delivery platform for Population Council's MPT Intravaginal Ring
Henry Schein introduces equipment repair subscription - Henry Schein Thrive Service Plus
Seres Therapeutics provides business updates and reports Q2 2023 financial results